… in several forms of cancers, yet with … role of chromatin remodeling and epigenetic mechanisms
in the regulation of angiogenesis and tumorigenesis. Many inhibitors of DNA methylation …

… However, the catalytic C-terminal domain of DNMT1 is the only DNA methyltransferase
domain which does not bear any catalytic activity when expressed separately. UHRF1 (ubiquitin …

… The regulation of DNA methylation, histone modifications, and noncoding RNAs turn into
candidates for epigenetic therapy. Among them, disruption of DNA methylation is demonstrated …

… in these aberrant modifications could be potential new targets of epigenetic therapy. For
instance, lysine … This chapter focuses on DNA methyltransferase inhibitors (DNMTi), histone …

… in glioblastoma multiforme and triple negative breast cancer (TNBC) are providing … inhibitors
along with DNA methyl transferase inhibitors and histone methyl transferase inhibitors are in …

… DNA methylation and Histone modifications which are associated with different types of
cancers… LIMITATIONS The major limitation of epigenetic therapies is the lack of specificity. Drugs …

… are struggling to make sense of their new data sets,[Citation68] reviewed in Ref.[Citation69]. …
Advances in the field of epigenetic therapy of cancer require not only the development of …

… epigenetic targets to be addressed for drug development and several inhibitors of DNA
methyltransferases, … Drug Administration (FDA) for clinical use in cancers [31]. In contrast, histone …

… epigenetic regulation of OC drug resistance and propose the potential clinical implications
of epigenetic therapies … reversing histone modifications and DNA methylation or by targeting …

… treatment of myelodysplastic syndrome, thus opening the floodgate for a whole new approach
to cancer therapy—epigenetic therapy… different epigenetic therapies (DNA methylation and …